Patent · US Active

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

US8008292B2 · kind B2 · utility

1Cited by

17References

6Claims

0Family size

Assignee

JAPAN TOBACCO INC. · JP

Inventors

Yoshihisa Koga · Takatsuki, JP
Shinji Yata · Takatsuki, JP
Takashi Watanabe · Yokohama, JP
Takuya Matsuo · Osaka, JP
Takayuki Yamasaki · Shunan, JP
Masahiro Sakata · Takatsuki, JP
Wataru Kondo · Takatsuki, JP
Hidekazu Ozeki · Takatsuki, JP
Yoshikazu Hori · Takatsuki, JP

Key dates

Filing date	Jul 15, 2005
Grant date	Aug 30, 2011
Priority date	—
Expiry date	Nov 28, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.